Soligenix, Inc. announced on March 25, 2025, the publication of preclinical efficacy data for CiVax™, its thermostabilized subunit vaccine candidate against SARS-CoV-2. The study, published in COVID, described that a CiVax™ booster combined with a primary adenovirus vaccine induced broader protection against COVID-19 variants in non-human primates.
This broader protection was observed compared to a two-shot mRNA vaccination series in humans. CiVax™ leverages Soligenix's proprietary ThermoVax® platform, which enables the vaccine to be heat-stable for at least one year at 40°C, simplifying storage and distribution logistics globally.
The ability of CiVax™ to induce rapid, broad immune coverage, even when administered after other primary vaccination series, represents a significant advantage. This platform technology also holds promise for preparing for future pandemics by offering a safe and easily distributable vaccine option.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.